Expanded access programmes: patient interests versus clinical trial integrity

被引：10

作者：

Lorigan, Paul ^{[1
]}

Ascierto, Paolo A. ^{[2
]}

Dummer, Reinhard ^{[3
]}

Eggermont, Alexander M.

Flaherty, Keith T. ^{[4
]}

Garbe, Claus ^{[5
]}

Gogas, Helen ^{[6
]}

Hauschild, Axel ^{[7
]}

Kefford, Richard F. ^{[8
,9
,10
]}

Kirkwood, John M. ^{[12
]}

Larkin, James ^{[13
]}

Long, Georgina V. ^{[8
,9
]}

Maio, Michele ^{[11
]}

McArthur, Grant A. ^{[14
,15
]}

Ribas, Antoni ^{[16
]}

Robert, Caroline ^{[17
]}

Schadendorf, Dirk

Sondak, Vernon K. ^{[18
]}

Wolchok, Jedd D. ^{[19
]}

Hudson, Andrew M. ^{[1
]}

机构：

[1] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Fdn Pascale, Ist Nazl Tumori, Naples, Italy

[3] Univ Zurich, Zurich, Switzerland

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Univ Med Ctr Tubingen, Tubingen, Germany

[6] Univ Athens, Dept Med, Athens, Greece

[7] Univ Hosp Schleswig Holstein, Kiel, Germany

[8] Melanoma Inst Australia, Sydney, NSW, Australia

[9] Univ Sydney, Sydney, NSW 2006, Australia

[10] Macquarie Univ, Sydney, NSW 2109, Australia

[11] Univ Hosp Siena, Siena, Italy

[12] Univ Pittsburgh, Melanoma Program, Inst Canc, Pittsburgh, PA USA

[13] Royal Marsden Hosp NHS Fdn Trust, London, England

[14] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia

[15] Univ Melbourne, Parkville, Vic 3052, Australia

[16] Univ Calif Los Angeles, Los Angeles, CA USA

[17] INSERM U981, Villejuif, France

[18] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[19] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

LANCET ONCOLOGY | 2015年 / 16卷 / 01期

关键词：

ADVANCED MELANOMA; TREMELIMUMAB; IPILIMUMAB; NIVOLUMAB; SURVIVAL;

D O I：

10.1016/S1470-2045(14)71161-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：15 / 17

页数：3

共 10 条

[1]

[Anonymous], JAMA

[2]

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials [J].

Flaherty, Keith T. ;

Hennig, Michael ;

Lee, Sandra J. ;

Ascierto, Paolo A. ;

Dummer, Reinhard ;

Eggermont, Alexander M. M. ;

Hauschild, Axel ;

Kefford, Richard ;

Kirkwood, John M. ;

Long, Georgina V. ;

Lorigan, Paul ;

Mackensen, Andreas ;

McArthur, Grant ;

O'Day, Steven ;

Patel, Poulam M. ;

Robert, Caroline ;

Schadendorf, Dirk .

LANCET ONCOLOGY, 2014, 15 (03) :297-304

[3]

Medicines and Healthcare products Regulatory Agency, 2014, EARL ACC MED SCHEM

[4]

Is Tremelimumab Beneficial in Advanced Melanoma? Reply [J].

Ribas, Antoni ;

Hauschild, Axel ;

Kefford, Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (22) :2836-2837

[5]

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma [J].

Ribas, Antoni ;

Kefford, Richard ;

Marshall, Margaret A. ;

Punt, Cornelis J. A. ;

Haanen, John B. ;

Marmol, Maribel ;

Garbe, Claus ;

Gogas, Helen ;

Schachter, Jacob ;

Linette, Gerald ;

Lorigan, Paul ;

Kendra, Kari L. ;

Maio, Michele ;

Trefzer, Uwe ;

Smylie, Michael ;

McArthur, Grant A. ;

Dreno, Brigitte ;

Nathan, Paul D. ;

Mackiewicz, Jacek ;

Kirkwood, John M. ;

Gomez-Navarro, Jesus ;

Huang, Bo ;

Pavlov, Dmitri ;

Hauschild, Axel .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :616-622

[6]

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial [J].

Robert, Caroline ;

Ribas, Antoni ;

Wolchok, Jedd D. ;

Hodi, F. Stephen ;

Hamid, Omid ;

Kefford, Richard ;

Weber, Jeffrey S. ;

Joshua, Anthony M. ;

Hwu, Wen-Jen ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Dronca, Roxana ;

Zarour, Hassane ;

Joseph, Richard W. ;

Boasberg, Peter ;

Chmielowski, Bartosz ;

Mateus, Christine ;

Postow, Michael A. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Li, Xiaoyun Nicole ;

Iannone, Robert ;

Ebbinghaus, Scot W. ;

Kang, S. Peter ;

Daud, Adil .

LANCET, 2014, 384 (9948) :1109-1117

[7]

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab [J].

Topalian, Suzanne L. ;

Sznol, Mario ;

McDermott, David F. ;

Kluger, Harriet M. ;

Carvajal, Richard D. ;

Sharfman, William H. ;

Brahmer, Julie R. ;

Lawrence, Donald P. ;

Atkins, Michael B. ;

Powderly, John D. ;

Leming, Philip D. ;

Lipson, Evan J. ;

Puzanov, Igor ;

Smith, David C. ;

Taube, Janis M. ;

Wigginton, Jon M. ;

Kollia, Georgia D. ;

Gupta, Ashok ;

Pardoll, Drew M. ;

Sosman, Jeffrey A. ;

Hodi, F. Stephen .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) :1020-+

[8]

US Food and Drug Administration, 2014, FIN RUL EXP ACC INV

[9]

Nivolumab plus Ipilimumab in Advanced Melanoma [J].

Wolchok, Jedd D. ;

Kluger, Harriet ;

Callahan, Margaret K. ;

Postow, Michael A. ;

Rizvi, Naiyer A. ;

Lesokhin, Alexander M. ;

Segal, Neil H. ;

Ariyan, Charlotte E. ;

Gordon, Ruth-Ann ;

Reed, Kathleen ;

Burke, Matthew M. ;

Caldwell, Anne ;

Kronenberg, Stephanie A. ;

Agunwamba, Blessing U. ;

Zhang, Xiaoling ;

Lowy, Israel ;

Inzunza, Hector David ;

Feely, William ;

Horak, Christine E. ;

Hong, Quan ;

Korman, Alan J. ;

Wigginton, Jon M. ;

Gupta, Ashok ;

Sznol, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :122-133

[10]

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria [J].

Wolchok, Jedd D. ;

Hoos, Axel ;

O'Day, Steven ;

Weber, Jeffrey S. ;

Hamid, Omid ;

Lebbe, Celeste ;

Maio, Michele ;

Binder, Michael ;

Bohnsack, Oliver ;

Nichol, Geoffrey ;

Humphrey, Rachel ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2009, 15 (23) :7412-7420

← 1 →